Julphar announces supply agreement with Hualan Biological Bacterin Co. Ltd for H1N1 vaccine

Enlarge Image

RELATED ARTICLES

• Dutch-Israeli firms sign license agreement for West Nile veterinary vaccine
• Iran: 2.5 million F&M vaccines distributed
• Julphar launches new pharmaceutical production plant

Gulf Pharmaceutical Industries (Julphar), the leading manufacturer of pharmaceuticals in the U.A.E. based in Ras Al Khaimah, has announced that it has signed an agreement with Hualan Biological Bacterin Co. Ltd, a leading provider of biopharmaceutical products, for the supply and marketing in the Middle East and North Africa (MENA) region of Hualan’s H1N1 vaccine, which is a single shot vaccine.

The agreement follows intense discussions between Julphar and Health Authorities in the MENA Region, culminated by meetings in Beijing between top management of Hualan and Julphar.

The deal gives Julphar exclusive rights to represent Hualan in all discussions with Authorities in MENA Region surrounding Hualan’s H1N1 vaccine. According to the Agreement, Hualan is to deliver enough doses of A (H1N1) Influenza Vaccine to satisfy all the needs of the region. The H1N1 vaccine will be manufactured in Julphar. Hualan has already supplied and delivered doses of A (H1N1) Influenza Vaccine in the market.

Dr. Ayman Sahli, General Manager of Julphar commented, “We chose Hualan as our partner because they offer the most credible and best possible option in the market for a product of the highest quality that can be readily available to fulfill the need of the whole region. Julphar is very glad to be able to bring this vaccine to MENA and we are confident that we can fulfill orders in a timely manner.”

Hualan obtained the viral seed particles of H1N1 vaccine from WHO on 3 June 2009 and completed the study on 22 July 2009. Hualan Bio is reported as the first company world wide to enter clinical trials for Pandemic H1N1 Influenza vaccine. With high expectations for Hualan’s enormous capacity to produce qualified Pandemic H1N1 vaccine, China sFDA top authorities are satisfied that Hualan has the efficacy to perform and deliver on time.

Hualan Biological Bacterin Co. Ltd. is a China-based biopharmaceutical company listed on the Stock Exchange that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Hualan's pandemic influenza vaccine (H1N1) has already been approved for China government stockpiling.

Hualan is the largest producer of vaccine in Asia with a state of the art facility that operates according to sFDA GMP and EU guidelines. The company has been long cooperating with well established Research Centers across the world.